Arrowhead Options Obesity-Fighting Technology
from MD Anderson Cancer Center
August 10, 2010 07:03 AM Eastern Daylight Time
PASADENA, Calif.--(EON: Enhanced Online News)--Arrowhead Research Corporation (NASDAQ:
ARWR) today announced that it has signed an option agreement with The University of Texas MD Anderson
Cancer Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat tissue by
specifically targeting the blood vessels that supply it. The technology was developed in the laboratory of Drs. Renata
Pasqualini and Wadih Arap at MD Anderson in Houston, Texas. Arrowhead sees the technology platform as an
attractive candidate around which to form a new majority-owned subsidiary to steer the technology through clinical
“We’ve been tracking obesity and metabolic markets for some time and have been searching for technology with the
potential of serving these markets in a unique and powerful way,” said Christopher Anzalone, Arrowhead’s CEO.
“We believe the platform that Drs. Pasqualini and Arap have developed may represent a great leap forward in
treating obesity, a condition with significant quality of life issues and virtually unparalleled direct and indirect
economic costs. This is also a relatively advanced program from a development standpoint and could be ready to
begin human clinical trials in the near term.”
The breakthrough approach was first published in the prestigious scientific journal Nature Medicine in May 2004
and received widespread media attention, including write-ups in the Wall Street Journal and the New York Times.
Since 2004, Drs. Pasqualini and Arap have worked to refine the technology and complete preclinical efficacy and
toxicity testing in preparation for clinical trials.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology
company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is see